A review on Patient Compliance and Response to Anticoagulant Therapy in Cardiovascular Disease Management
Keywords:
Anticoagulant therapy, Patient adherence, Direct oral anticoagulants (DOACs), Therapeutic drug monitoringAbstract
Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, with anticoagulant therapy playing a critical role in preventing thromboembolic events. Despite the efficacy of these treatments, patient compliance remains a significant challenge, influencing clinical outcomes and healthcare costs. This review examines the factors affecting adherence to anticoagulant therapy, the impact of novel anticoagulants on compliance rates, and the clinical consequences of non-adherence. By assessing existing literature and patient case studies, this article highlights barriers to optimal treatment adherence and proposes strategies to enhance patient compliance and therapeutic efficacy in cardiovascular disease management.
Downloads
References
World Health Organization Cardiovascular diseases (CVDs) 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) [15 Nov 2021]. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
National Institute for Health and Care Excellence CVD risk assessment and management. 2020. https://cks.nice.org.uk/topics/cvd-risk-assessment-management. [15 Nov 2021]. https://cks.nice.org.uk/topics/cvd-risk-assessment-management
Global Health Data Exchange GBD results tool. 2020. http://ghdx.healthdata.org/gbd-results-tool. [15 Nov 2021]. http://ghdx.healthdata.org/gbd-results-tool
World Health Organization The future of CVD. 2004. https://www.who.int/cardiovascular_diseases/en/cvd_atlas_25_future.pdf. [15 Nov 2021]. https://www.who.int/cardiovascular_diseases/en/cvd_atlas_25_future.pdf
Office for National Statistics Deaths registered in England and Wales — 21st century mortality. 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/the21stcenturymortalityfilesdeathsdataset. [15 Nov 2021]. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/the21stcenturymortalityfilesdeathsdataset
World Health Organization Diseases of the circulatory system (I00-I99). In: International Statistical Classification of Diseases and Related Health Problems 10th Revision . 2019. https://icd.who.int/browse10/2019/en#/IX. [15 Nov 2021
Lewer D, Jayatunga W, Aldridge RW, et al. Premature mortality attributable to socioeconomic inequality in England between 2003 and 2018: an observational study. Lancet Public Health. 2020;5(1):e33–e41. doi: 10.1016/S2468-2667(19)30219-1
Ho KH, van Hove M, Leng G. Trends in anticoagulant prescribing: a review of local policies in English primary care. BMC Health Serv Res. 2020;20(1):279.
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492–501
Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med. 2015;16(1):11–17.
Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–19
Reversal of Anticoagulation: Protamine. Pharmacology in the Catheterization Laboratory.
Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis. JAMA. 1996; 276(10): 811-815.
Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 1995; 26(2): 313-318
Swahn E, Wallentin L. Low-molecular-weight heparin (fragmin) during instability in coronary artery disease (FRISC). Am J Cardiol. 1997; 80(5): 25E-29E
Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997; 337(7): 447-452.
Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999; 100(15): 1593-1601.
Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003; 107(2): 238-244.
Magee KD, Sevcik W, Moher D, Rowe BH. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane Database Syst Rev. 2003;(1): CD002132.
Mahaffey KW, Cohen M, Garg J, et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA. 2005; 294(20): 2594-2600.
Drouet L, Bal dit Sollier C, Martin J. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. Am Heart J. 2009; 158(2): 177-184.
Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(3): 267-315.
Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004; 292(1): 89-96.
Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354(14): 1464-1476.
Schomig A, Sarafoff N, Seyfarth M. Triple antithrombotic management after stent implantation: when and how? Heart. 2009; 95(15): 1280-1285.
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2016; 152(5): 1243-1275.
Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213-260.
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016; 68(10): 1082-1115.
Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381(9872): 1107-1115.
Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016; 375(25): 2423-2434
Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377(16): 1513-1524.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981-992.
Katritsis DG, Gersh BJ, Camm AJ. Anticoagulation in atrial fibrillation – current concepts. Arrhythm Electrophysiol Rev. 2015; 4(2): 100-107.
Writing Committee M, January CT, Wann LS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23): e199-e267.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50(5): e1-e88.
Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review. Patient. 2017; 10(1): 17-37.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12): 857-867
Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991; 84(2): 527-539
van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009; 40(4): 1410-1416.
Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells. 2022 Oct 13;11(20):3214. doi: 10.3390/cells11203214. PMID: 36291080; PMCID: PMC9600347.
Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace. 2014; 16(5): 631-638
McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006; 119(8): 624-638
Bien JY, Tao DL, Daughety MM, DeLoughery TG, Shatzel JJ. More efficacious, equally safe: a meta-analysis comparing the safety of direct oral anticoagulants versus aspirin. J Thromb Thrombolysis. 2018; 46(1): 22-23.
Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360(20): 2066-2078.
Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367(9526): 1903-1912.
Katritsis DG, Gersh BJ, Camm AJ. Anticoagulation in Atrial Fibrillation - Current Concepts. Arrhythm Electrophysiol Rev. 2015; 4(2): 100-107
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-1151
Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364(9): 806-817.
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013; 369(22): 2093-2104.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-891.
Ferri N., Colombo E., Tenconi M., Baldessin L., Corsini A. Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. Pharmaceutics. 2022;14:1120.
Raymond J., Imbert L., Cousin T., Duflot T., Varin R., Wils J., Lamoureux F. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J. Pers. Med. 2021;11:37
Steffel J., Collins R., Antz M., Cornu P., Desteghe L., Haeusler K.G., Oldgren J., Reinecke H., Roldan-Schilling V., Rowell N., et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Eur. 2021;23:1612–1676
Gibbons J.A., de Vries M., Krauwinkel W., Ohtsu Y., Noukens J., van der Walt J., Mol R., Mordenti J., Ouatas T. Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clin. Pharmacokinet. 2015;54:1057–1069.
Li A., Li M.K., Crowther M., Vazquez S.R. Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. Thromb. Res. 2020;194:240–245
Baillargeon J., Holmes H.M., Lin Y., Raji M.A., Sharma G., Kuo Y. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am. J. Med. 2012;125:183–189.
Forbes H.L., Polasek T.M. Potential drug–drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther. Adv. Drug Saf. 2017;8:319–328
McDonough C.W. Pharmacogenomics in Cardiovascular Diseases. Curr. Protoc. 2021;1:e189.
Padrini R. Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure. Eur. J. Drug Metab. Pharmacokinet. 2019;44:1–12.
Ballestri S., Capitelli M., Fontana M.C., Arioli D., Romagnoli E., Graziosi C., Lonardo A., Marietta M., Dentali F., Cioni G. Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. Adv. Ther. 2020;37:1910–1932.
Caldwell P.H.Y., Murphy S.B., Butow P.N., Craig J.C. Clinical trials in children. Lancet. 2004;364:803–811. doi: 10.1016/S0140-6736(04)16942-0
Male C., Lensing A.W.A., Palumbo J.S., Kumar R., Nurmeev I., Hege K., Bonnet D., Connor P., Hooimeijer H.L., Torres M. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: A randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7:e18–e27.
Beyer-Westendorf J., Tittl L., Bistervels I., Middeldorp S., Schaefer C., Paulus W., Thomas W., Kemkes-Matthes B., Sandra Marten S., Bornhauser M. Safety of direct oral anticoagulant exposure during pregnancy: A retrospective cohort study. Lancet Haematol. 2020;7:e884–e891.
Wiesen M.H.J., Blaich C., Müller C., Streichert T., Pfister R., Michels G. The Direct Factor Xa Inhibitor Rivaroxaban Passes Into Human Breast Milk. Chest. 2016;150:e1–e4
Daei M., Khalili H., Heidari Z. Direct oral anticoagulant safety during breastfeeding: A narrative review. Eur. J. Clin. Pharmacol. 2021;77:1465–1471.
Gebreyohannes EA, Mill D, Salter S, Chalmers L, Bereznicki L, Lee K. Strategies for improving guideline adherence of anticoagulants for patients with atrial fibrillation in primary healthcare: A systematic review. Thromb Res. 2021 Sep;205:128-136. doi: 10.1016/j.thromres.2021.07.014. Epub 2021 Jul 24. PMID: 34333301.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
